近日，顾金辉撰文系统阐述了大力发展卫生健康新质生产力的内涵与路径。文章指出，发展新质生产力是深入实施创新驱动发展战略的着力点和落脚点，卫生健康新质生产力已成为“十五五”时期卫生健康工作的重点任务，其核心在于发挥科技创新的要素作用，催生新产业、新模式、新动能。
发展新质生产力是党的二十届三中、四中全会及2023年以来历次中央经济工作会议部署的任务重点。《国民经济和社会发展第十五个五年规划纲要》明确提出“加快高水平科技自立自强，引领发展新质生产力”。2026年全国卫生健康工作会议将“大力发展卫生健康新质生产力”列为重点任务，进一步凸显其战略地位。
文章认为，卫生健康新质生产力内涵丰富，既包括以公益性为导向的医疗卫生服务业，也包括参与全球产业竞争的医药制造业。其集中体现在以科技创新支撑服务与产品的质量、效率和附加值的提升，推动行业从规模扩张向高质量发展转型。
在医疗卫生服务方面，我国已建成世界上规模最大、效率较高的医疗卫生服务体系，卫生资源与服务总量达到较高水平，机构运营和人员效率明显提升。下一步应着力发挥科技创新的核心支撑作用，强化科技创新在构建公平可及、系统连续、优质高效的医疗卫生服务体系中的促进作用，通过新技术的创新与应用提高诊疗效果，实现卫生体系资源效率和系统绩效的进一步提升。
在医药制造产业方面，我国在研药物总数超过7000款，居世界第二位；2025年对外授权交易合同金额超过1300亿美元，是2024年的2.5倍；15款国产创新药进入美国、欧洲等市场，泽布替尼和西达基奥仑赛销售额进入全球前100强，6家企业进入全球药企50强。但产业总规模较小、平均利润率较低，必须进一步推进以科技驱动高技术、高质量、高竞争力与附加值的医药制造产业发展，推动形成支柱产业规模。
在政策路径上，国家卫生健康委主要通过强化卫生健康领域科技管理，催生引领卫生健康新质生产力。以临床研究的规范化管理为着力点，推动新技术从研究到应用转化的效率提升，加速“技术—临床”“成果—产业/临床”“产品—产业”的价值化路径。
其中，“技术—临床”路径以新技术支撑医疗卫生服务新质生产力发展，打通研究者发起的临床研究、临床诊疗新技术、医保支付服务项目之间的技术转化通道，促进新技术快速应用于临床，提升服务质量和效率。
可以预见，随着政策框架逐步完善，卫生健康新质生产力将从理念走向实践，推动我国从医疗卫生大国向强国迈进，为健康中国建设注入强劲动力，并为全球健康事业发展贡献中国智慧和中国方案。
Recently, Gu Jinhui wrote an article systematically elaborating on the connotation and path of vigorously developing new quality productive forces in health. The article points out that developing new quality productive forces is the focus and foothold of deeply implementing the innovation-driven development strategy. New quality productive forces in health have become a key task of health work during the "15th Five-Year Plan" period, with the core being to leverage the role of technological innovation as a factor of production to spawn new industries, new models, and new drivers.
Developing new quality productive forces is a key task deployed by the Third and Fourth Plenary Sessions of the 20th CPC Central Committee and the Central Economic Work Conferences since 2023. The Outline of the 15th Five-Year Plan for National Economic and Social Development clearly proposes to "accelerate high-level scientific and technological self-reliance and lead the development of new quality productive forces." The 2026 National Health Work Conference listed "vigorously developing new quality productive forces in health" as a key task, further highlighting its strategic position.
The article holds that new quality productive forces in health have rich connotations, including both the public welfare-oriented medical and health service industry and the pharmaceutical manufacturing industry that participates in global industrial competition. They are concentrated in the use of technological innovation to support the improvement of quality, efficiency, and added value of services and products, promoting the transformation of the industry from scale expansion to high-quality development.
In terms of medical and health services, China has built the world's largest and relatively efficient medical and health service system, with total health resources and services reaching a high level, and institutional operation and personnel efficiency significantly improved. The next step should focus on giving full play to the core supporting role of technological innovation, strengthening the promoting role of technological innovation in building a fair, accessible, systematic, continuous, high-quality, and efficient medical and health service system, improving diagnosis and treatment outcomes through the innovation and application of new technologies, and further enhancing the resource efficiency and system performance of the health system.
In terms of the pharmaceutical manufacturing industry, China has more than 7,000 drugs under research, ranking second in the world; in 2025, the contract amount of out-licensing transactions exceeded 130 billion US dollars, 2.5 times that of 2024; 15 domestic innovative drugs entered markets such as the United States and Europe, with sales of zanubrutinib and ciltacabtagene autoleucel entering the global top 100, and 6 companies entering the global top 50 pharmaceutical companies. However, the overall industry scale is relatively small and the average profit margin is low. It is necessary to further promote the development of a pharmaceutical manufacturing industry driven by science and technology with high technology, high quality, high competitiveness, and high added value, and promote the formation of a pillar industry scale.
In terms of policy paths, the National Health Commission mainly strengthens scientific and technological management in the health field to spawn and lead new quality productive forces in health. Focusing on the standardized management of clinical research, it promotes the efficiency of the transformation of new technologies from research to application, and accelerates the value-added paths of "technology-clinical practice," "achievements-industry/clinical practice," and "products-industry."
Among them, the "technology-clinical practice" path uses new technologies to support the development of new quality productive forces in medical and health services, opening up the technology transformation channel among investigator-initiated clinical research, new clinical diagnosis and treatment technologies, and medical insurance payment service items, promoting the rapid application of new technologies in clinical practice, and improving service quality and efficiency.
It can be foreseen that as the policy framework gradually improves, new quality productive forces in health will move from concept to practice, promoting China's progress from a large country in medical and health care to a strong one, injecting strong impetus into the construction of a Healthy China, and contributing Chinese wisdom and Chinese solutions to the development of global health.